ArticlePLoS pathogens2025
Epstein-Barr virus-transformed B-cells from a hypoxia model of the germinal center requires external unsaturated fatty acids.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A guide to B cell metabolism.Nature reviews. Immunology · 2026Review
- Targeting Host Metabolic and Epigenetic Rewiring Blocks Lytic Gammaherpesvirus Production.Viruses · 2026Article
- Stage-specific regulation of KSHV infection by HIF-1α.Journal of virology · 2026Article
- Fueling silence: Metabolic control of latent viral infection.PLoS pathogens · 2026Article
- Epstein-Barr Virus Latent Membrane Protein 1 Suppresses Ferroptosis via Pentose Phosphate Pathway and Glutathione Metabolism.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
Epstein-Barr virus (EBV) drives over 200,000 cancer cases annually, including diffuse large B-cell lymphoma, Burkitt lymphoma, and classic Hodgkin lymphoma-malignancies that frequently originate from germinal centers (GCs), which are physiologically hypoxic (O2 < 1%). However, conventional transformation models are typically conducted under 21% O2-an artificial condition that fails to replicate the hypoxic GC microenvironment and may obscure critical metabolic vulnerabilities that are therapeutically targetable. Therefore, therapeutic targets identified under 21% O2 conditions may not fully translate to the hypoxic environment of lymphoid tissues, which could limit their effectiveness in vivo. To overcome these limitations, we developed an ex vivo model of EBV-driven B-cell transformation under 1% O2, mimicking GC hypoxia. Under 1% O2, EBV efficiently transformed primary human B-cells, inducing hallmark oncogenic programs and activating super-enhancers at key loci including MYC and IRF4. Multi-omic profiling revealed a distinct hypoxia-adapted metabolic state, characterized by suppressed fatty acid synthesis, enhanced glycolysis and glycerophospholipid metabolism, and increased triglyceride storage in lipid droplets. These adaptations alleviate lipotoxic stress and maintain redox balance but render transformed cells highly dependent on external unsaturated fatty acids. Inhibition of triglyceride synthesis using the DGAT1 inhibitor A922500 selectively impaired proliferation and survival of EBV-transformed B-cells under GC-like hypoxia. These findings define key metabolic dependencies shaped by the hypoxic GC microenvironment and establish a physiologically relevant platform for studying EBV-driven B-cell transformation. Our work highlights the importance of modeling physiological oxygen tension and suggests that targeting lipid uptake and storage pathways may offer new therapeutic opportunities for halting EBV transformation with hypoxic tissue niches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.